Profound Dermal and SubQ Cartridges for the Treatment of Cellulite

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

31 participants

Study Classification

INTERVENTIONAL

Study Start Date

2017-09-13

Study Completion Date

2019-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Clinical Study to Evaluate the Performance of the Profound System for the Treatment of Cellulite.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Clinical Feasibility Study to Evaluate the Safety and Performance of the Profound Matrix System

NCT06157567

Skin Laxity Wrinkle Skin Condition

ACTIVE_NOT_RECRUITING NA

Treatment With the Profound System for Submental Laxity

NCT02595216

Submental Laxity

UNKNOWN NA

Performance of the ePrime System for Cellulite

NCT02489994

Cellulite

UNKNOWN NA

EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)

NCT02724644

Edematous Fibrosclerotic Panniculopathy Cellulite

COMPLETED PHASE2

Treatment for Cellulite Appearance

NCT05358847

Cellulite

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Up to 60 healthy female volunteers, seeking cellulite treatment, 18 to 60 years of age from up to 3 investigational sites.

Prospective, open-label, baseline-controlled, two arms, randomized, clinical study to evaluate the Profound device using the Dermal and SubQ Cartridges for minimally-invasive treatment of the upper thighs and buttocks cellulite appearance.

The treatment areas of the study subjects will be divided into two arms:

1. Arm 1 - the upper thigh/buttock on the left or right side of the body will undergo a single Profound treatment utilizing the Dermal and SubQ Cartridges
2. Arm 2 - the contralateral upper thigh/buttock side of the body will undergo a single Profound treatment utilizing the SubQ Cartridge only.

Methodology described in protocol to evaluate efficacy of treatments will be carried out at each visit.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cellulite

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Profound treatment to small areas

Single Profound treatment with the Dermal and/or SubQ cartridges to bra bulge, above the knees or upper arms

Group Type EXPERIMENTAL

Profound

Intervention Type DEVICE

The main intent of the Profound Dermal and Subdermal cartridges for cellulite treatment is to utilize a minimally-invasive approach to directly deliver radiofrequency (RF) energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Profound

The main intent of the Profound Dermal and Subdermal cartridges for cellulite treatment is to utilize a minimally-invasive approach to directly deliver radiofrequency (RF) energy into tissue through pairs of micro-electrode needles and use temperature sensors within the needles to reliably create fractional thermal injuries within the skin.

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Signed informed consent to participate in the study.
2. Female subjects, ≥ 18 and ≤ 60 years of age at the time of enrollment
3. Fitzpatrick Skin Type I to VI.
4. Subjects seeking treatment of cellulite in the upper thighs and buttocks areas.
5. Subject cellulite stage II or III as graded using Nurnberger-Muller scale classification (Appendix III).
6. Not pregnant, lactating and must be either post-menopausal, surgically sterilized, or using a medically acceptable form of birth control at least 3 months prior to enrollment (i.e., oral contraceptives, contraceptive implant, barrier methods with spermicide or abstinence).
7. Negative urine pregnancy test as tested prior to each treatment and at the last visit for women of child bearing potential (e.g. not menopause).
8. General good health confirmed by medical history and skin examination of the treated area.
9. Willing to receive the proposed Profound treatment.
10. Willing to follow the treatment and follow-up schedule and post-treatment care instructions.
11. Willing to have photographs and images taken of the treated areas to be used de-identified in evaluations, publications and presentations.

Exclusion Criteria

1. Subject cellulite stage 0 or I as graded using Nurnberger-Muller scale classification (Appendix III).
2. Subject had surgery or any other procedure for cellulite in the last 6 months.
3. Pregnant or planning to become pregnant, having given birth less than 3 months ago, and/or breast feeding.
4. Known allergy to lidocaine or epinephrine or antibiotics.
5. Active malignancy or history of malignancy in the past 5 years.
6. Having any active electrical implant anywhere in the body, such as a pacemaker or an internal defibrillator.
7. Suffering from significant concurrent illness, such as cardiac disorders, diabetes (type I or II), lupus, porphyria, or pertinent neurological disorders (i.e. any disease state that in the opinion of the Physician would interfere with the anesthesia, treatment, or healing process).
8. Having a known anti-coagulative or thromboembolic condition or taking anticoagulation medications one week prior to and during the treatment course (to allow inclusion, temporary cessation of use as per the subject's physician discretion).
9. History of immunosuppression/immune deficiency disorders (including HIV infection or AIDS) or currently using immunosuppressive medications.
10. Suffering from hormonal imbalance, whether related to thyroid, pituitary, or androgen.
11. History of significant lymphatic drainage problems.
12. History of cancer which required lymph node biopsy or dissection.
13. Suffering from significant skin conditions in treatment areas or inflammatory skin conditions, including, but not limited to, open lacerations or abrasions, hidradenitis, or dermatitis of the treatment area prior to treatment (duration of resolution as per the Investigator's discretion) or during the treatment course.
14. History of keloid scarring, abnormal wound healing and / or prone to bruising.
15. History of epidermal or dermal disorders (particularly if involving collagen or microvascularity), including collagen vascular disease or vasculitic disorders.
16. Use of isotretinoin (Accutane) within 6 months of treatment or during the study.
17. Subject on systemic corticosteroid therapy 6 months prior to and throughout the course of the study.
18. Dysplastic nevi in the area to be treated.
19. Participation in a study of another device or drug within 3 month prior to enrollment or during this study.
20. Subject has palpable lymphadenopathy at any visit. Standard palpation techniques will be used.
21. Subjects with history of severe edema.
22. As per the Investigator's discretion, any physical or mental condition that might make it unsafe for subject to participate in this study.

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes